	US 11,993,646 B2
	Compositions and methods for modified b cells expressing reassigned biological agents
Roderick A. Hyde, Redmond, WA (US); Wayne R. Kindsvogel, Seattle, WA (US); and Gary L. McKnight, Bothell, WA (US)
Assigned to KOTA BIOTHERAPEUTICS, LLC, Bellevue, WA (US)
Filed by KOTA BIOTHERAPEUTICS, LLC, Bellevue, WA (US)
Filed on Aug. 17, 2020, as Appl. No. 16/994,837.
Application 16/994,837 is a continuation of application No. 15/924,898, filed on Mar. 19, 2018, granted, now 10,745,468, issued on Aug. 18, 2020.
Application 15/924,898 is a continuation in part of application No. 15/178,715, filed on Jun. 10, 2016, granted, now 10,233,424, issued on Mar. 19, 2019.
Application 15/178,715 is a continuation in part of application No. 14/549,685, filed on Nov. 21, 2014, granted, now 9,512,213, issued on Dec. 6, 2016.
Application 14/549,685 is a continuation of application No. 13/374,351, filed on Dec. 22, 2011, granted, now 9,175,072.
Prior Publication US 2021/0095010 A1, Apr. 1, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/10 (2006.01); A61K 39/00 (2006.01); C07K 16/00 (2006.01); C07K 16/10 (2006.01); C07K 16/12 (2006.01); C07K 16/18 (2006.01); C07K 16/30 (2006.01); C07K 16/44 (2006.01); C12N 5/0781 (2010.01); G01N 33/68 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 39/00 (2013.01); C07K 16/00 (2013.01); C07K 16/1018 (2013.01); C07K 16/109 (2013.01); C07K 16/1271 (2013.01); C07K 16/3069 (2013.01); C07K 16/44 (2013.01); C12N 5/0635 (2013.01); G01N 33/6854 (2013.01); A61K 2039/505 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/14 (2013.01); C07K 2317/33 (2013.01); C07K 2317/76 (2013.01); C12N 2510/00 (2013.01)]

23 Claims

1. A modified B cell of expressing:

at least one exogenously incorporated membrane immunoglobulin or a recombinant receptor that at least does one of binding to a first antigen and is stimulated by a first antigen;

at least one exogenously incorporated reassigned biological agent, and

at least one endogenous secreted immunoglobulin reactive to a second antigen.